Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
Arch. endocrinol. metab. (Online)
; 65(2): 242-247, Mar.-Apr. 2021. graf
Article
em En
| LILACS
| ID: biblio-1248808
Biblioteca responsável:
BR1.1
ABSTRACT
SUMMARY Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
4_TD
Base de dados:
LILACS
Assunto principal:
Neoplasias da Glândula Tireoide
/
Carcinoma Anaplásico da Tireoide
/
COVID-19
Limite:
Humans
/
Male
Idioma:
En
Revista:
Arch. endocrinol. metab. (Online)
Ano de publicação:
2021
Tipo de documento:
Article